The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma

被引：38

作者：

Vauleon, Elodie

Auger, Nathalie

Benouaich-Amiel, Alexandra

Laigle-Donadey, Florence

Kaloshi, Gentian

Lejeune, Julie

Delattre, Jean-Yves

Thillet, Joelle

Sanson, Marc ^{[1
]}

机构：

[1] INSERM, U711 Biol Interact Neurones & Glie, F-75651 Paris 13, France

[2] Univ Paris 06, Fac Med, Paris, France

[3] Grp Hosp Pitie Salpetriere, Serv Neurol Mazarin, F-75013 Paris, France

来源：

CANCER GENETICS AND CYTOGENETICS | 2007年 / 172卷 / 01期

关键词：

D O I：

10.1016/j.cancergencyto.2006.07.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The A/G61 polymorphism located in the 5'UTR of the EGF gene has been found to be both a risk factor and a prognostic factor in glioblastoma (GBM), but the functional consequences have not been investigated. Here we show, in vitro, that this polymorphism is functional, in that the G allele promoter is 40% more active than the A variant (P < 0.001). However, analysis of a large series of 209 GBM patients and 214 control subjects did not confirm that A/G61 polymorphism is a significant risk factor for GBM, despite a trend for higher GG frequency in these patients. Furthermore, A/G61 polymorphism was not a prognostic factor for survival in GBM patients, although it does appear to affect progression-free survival. (c) 2007 Elsevier Inc. All rights reserved.

引用

收藏

页码：33 / 37

页数：5

相关论文

共 13 条

[1] EGF gene polymorphism and the risk of incident primary melanoma [J].

Amend, KL ;

Elder, JT ;

Tomsho, LP ;

Bonner, JD ;

Johnson, TM ;

Schwartz, J ;

Berwick, M ;

Gruber, SB .

CANCER RESEARCH, 2004, 64 (08) :2668-2672

[2] A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease [J].

Bhowmick, DA ;

Zhuang, ZP ;

Wait, SD ;

Weil, RJ .

CANCER RESEARCH, 2004, 64 (04) :1220-1223

[3] Signal transduction pathways and their relevance in human astrocytomas [J].

Feldkamp, MM ;

Lau, N ;

Guha, A .

JOURNAL OF NEURO-ONCOLOGY, 1997, 35 (03) :223-248

[4] The WHO classification of tumors of the nervous system [J].

Kleihues, P ;

Louis, DN ;

Scheithauer, BW ;

Rorke, LB ;

Reifenberger, G ;

Burger, PC ;

Cavenee, WK .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (03) :215-225

[5] Modulation of hepatic gene expression by hepatocyte nuclear factor 1 [J].

Ktistaki, E ;

Talianidis, I .

SCIENCE, 1997, 277 (5322) :109-112

[6] A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival [J].

Lacroix, M ;

Abi-Said, D ;

Fourney, DR ;

Gokaslan, ZL ;

Shi, WM ;

DeMonte, F ;

Lang, FF ;

McCutcheon, IE ;

Hassenbusch, SJ ;

Holland, E ;

Hess, K ;

Michael, C ;

Miller, D ;

Sawaya, R .

JOURNAL OF NEUROSURGERY, 2001, 95 (02) :190-198

[7] EGF+61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma [J].

McCarron, SL ;

Bateman, AC ;

Theaker, JM ;

Howell, WM .

INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :673-675

[8] A MUTANT EPIDERMAL GROWTH-FACTOR RECEPTOR COMMON IN HUMAN GLIOMA CONFERS ENHANCED TUMORIGENICITY [J].

NISHIKAWA, R ;

JI, XD ;

HARMON, RC ;

LAZAR, CS ;

GILL, GN ;

CAVENEE, WK ;

HUANG, HJS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7727-7731

[9] Genetic pathways to glioblastoma:: A population-based study [J].

Ohgaki, H ;

Dessen, P ;

Jourde, B ;

Horstmann, S ;

Nishikawa, T ;

Di Patre, PL ;

Burkhard, C ;

Schüler, D ;

Probst-Hensch, NM ;

Maiorka, PC ;

Baeza, N ;

Pisani, P ;

Yonekawa, Y ;

Yasargil, MG ;

Lütolf, UM ;

Kleihues, P .

CANCER RESEARCH, 2004, 64 (19) :6892-6899

[10] Epidemiology and etiology of gliomas [J].

Ohgaki, H ;

Kleihues, P .

ACTA NEUROPATHOLOGICA, 2005, 109 (01) :93-108